CN113896236A - Titanium dioxide synthesis method based on glutamine modification - Google Patents

Titanium dioxide synthesis method based on glutamine modification Download PDF

Info

Publication number
CN113896236A
CN113896236A CN202111067439.2A CN202111067439A CN113896236A CN 113896236 A CN113896236 A CN 113896236A CN 202111067439 A CN202111067439 A CN 202111067439A CN 113896236 A CN113896236 A CN 113896236A
Authority
CN
China
Prior art keywords
titanium dioxide
glutamine
image analysis
powder
mixed solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111067439.2A
Other languages
Chinese (zh)
Inventor
冒志磊
张丽娜
周军
王淮燕
秦志强
张克良
万婷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou Maternal And Child Health Care Hospital
Original Assignee
Changzhou Maternal And Child Health Care Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou Maternal And Child Health Care Hospital filed Critical Changzhou Maternal And Child Health Care Hospital
Priority to CN202111067439.2A priority Critical patent/CN113896236A/en
Priority to LU500966A priority patent/LU500966B1/en
Publication of CN113896236A publication Critical patent/CN113896236A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G23/00—Compounds of titanium
    • C01G23/04—Oxides; Hydroxides
    • C01G23/047—Titanium dioxide
    • C01G23/053—Producing by wet processes, e.g. hydrolysing titanium salts
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G23/00—Compounds of titanium
    • C01G23/04—Oxides; Hydroxides
    • C01G23/047—Titanium dioxide
    • C01G23/08—Drying; Calcining ; After treatment of titanium oxide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/3577—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing liquids, e.g. polluted water
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/02—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material
    • G01N23/04—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and forming images of the material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20008—Constructional details of analysers, e.g. characterised by X-ray source, detector or optical system; Accessories therefor; Preparing specimens therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/207—Diffractometry using detectors, e.g. using a probe in a central position and one or more displaceable detectors in circumferential positions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/22—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material
    • G01N23/2202—Preparing specimens therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/22—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material
    • G01N23/2206—Combination of two or more measurements, at least one measurement being that of secondary emission, e.g. combination of secondary electron [SE] measurement and back-scattered electron [BSE] measurement
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/60—Compounds characterised by their crystallite size
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/82—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by IR- or Raman-data
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/84—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by UV- or VIS- data
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/85—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by XPS, EDX or EDAX data
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/01—Particle morphology depicted by an image
    • C01P2004/03—Particle morphology depicted by an image obtained by SEM
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/30—Particle morphology extending in three dimensions
    • C01P2004/38—Particle morphology extending in three dimensions cube-like

Abstract

The invention discloses a method for synthesizing titanium dioxide based on glutamine modification, which belongs to the technical field of biological pharmacy and comprises the following steps: s1, selecting raw materials; s2, preparing a mixed solution A; s3, preparing a mixed solution B; s4, preparing sol; s5, preparing gel; s6, preparation of xerogel powder: drying the wet gel at 100 deg.C for 12 hr, grinding into powder, and calcining the powder at 300 deg.C for 1 hr to remove organic substances; s8, analyzing titanium dioxide. According to the glutamine modification-based titanium dioxide synthesis method, copper ions are doped into nano-particle lattices, lattice stability and lattice energy are reduced, and the copper ions and glutamine react under a neutral condition to obtain glutamine-modified nano-titanium dioxide, so that the glutamine is used for modifying the nano-titanium dioxide, the glutamine-nano-titanium dioxide is synthesized, and ultraviolet, infrared, SEM, EDX and XRD characterization is carried out on the glutamine-modified nano-titanium dioxide for verification.

Description

Titanium dioxide synthesis method based on glutamine modification
Technical Field
The invention belongs to the technical field of biological pharmacy, and particularly relates to a synthesis method of titanium dioxide based on glutamine modification.
Background
Cancer cells have the property of "glutamine addiction" in that they enrich glutamine in large amounts for their rapid growth, and therefore, although glutamine is the most abundant amino acid in the body, a deficiency of glutamine often occurs in tumor-bearing organisms, and thus the supplemented glutamine is rapidly transported to tumor tissues. Although in vitro cell research shows that glutamine can promote tumor cell proliferation, in vivo research results contradict with the results, and the parenteral or enteral nutrition support containing glutamine does not obviously promote tumor growth of tumor-bearing host, probably because glutamine can promote positive nitrogen balance of host and improve body immunity, so that it is safe to supplement glutamine to tumor-bearing body, and the research related to glutamine metabolism is gradually becoming a new target and breakthrough for cancer treatment. The tumor metastasis is inhibited by utilizing the low-toxicity ability but high-efficiency invasion and migration inhibition ability of the nano titanium dioxide, and the nano titanium dioxide is modified by utilizing glutamine, but cannot be directly modified due to large lattice bond energy of the nano titanium dioxide.
In order to solve the above problems, we propose a synthesis method of titanium dioxide based on glutamine modification.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a synthesis method of titanium dioxide based on glutamine modification, which aims to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a synthesis method of titanium dioxide based on glutamine modification comprises the following steps:
s1, selecting raw materials: providing a raw material for synthesizing glutamine modified titanium dioxide;
s2, preparing a mixed solution A: selecting butyl titanate, absolute ethyl alcohol and acetylacetone from raw materials, and mixing in a magnetic stirrer to obtain a mixed solution A;
s3, preparing a mixed solution B: selecting anhydrous ethanol and Cu (NO) from raw materials3)2Mixing the aqueous solution and concentrated HCl in a magnetic stirrer to obtain a mixed solution B;
s4, preparing sol: slowly dripping the mixed solution B into the mixed solution A to obtain sol with green color;
s5, preparing gel: putting the prepared sol into a magnetic stirrer, fully and uniformly mixing the sol and the magnetic stirrer, and standing and aging the sol to obtain wet gel;
s6, preparation of xerogel powder: drying the wet gel at 100 ℃ for 12h, grinding the dried gel into powder, roasting the powder at 300 ℃ for 1h to remove organic matters, roasting at 600 ℃ for 2h, and naturally cooling to room temperature to obtain dry gel powder;
s7, modified titanium dioxide: mixing and dissolving the xerogel powder and glutamine in deionized water, adjusting the pH value to 7 by using 0.1mol/L NaOH solution, and reacting for 6 hours to finish the modification of glutamine on titanium dioxide;
s8, analysis of titanium dioxide: and carrying out image analysis on the titanium dioxide modified by the glutamine.
Further optimizing the technical scheme, in S2, the mixing process of the mixed solution a includes the following specific contents: 10ml of butyl titanate was taken and put into a magnetic stirrer, and the butyl titanate was mixed with 8.6ml of absolute ethanol and 0.3ml of acetylacetone under magnetic stirring by the magnetic stirrer.
Further optimizing the technical scheme, in S3, the mixing process of the mixed solution B includes the following specific contents: under magnetic stirring with a magnetic stirrer, 8.6ml of absolute ethanol and 1.3ml of Cu (NO) with a mass concentration of 2%3)2The aqueous solution was mixed well with 0.1ml of concentrated HCl.
Further optimizing the technical scheme, in the step S5, the time for uniformly mixing the sol is 1h, and the temperature for standing and aging the sol is selected from room temperature conditions.
Further optimizing the technical scheme, in the S6, the prepared xerogel powder is modified by Cu2+Ionic titanium dioxide powder.
Further optimizing the technical scheme, in the S7, deionized water used for dissolving xerogel powder and glutamine is heated, and the heating range is 40-50 ℃.
Further optimizing the technical solution, in S8, the image analysis method includes an SEM image analysis method, an XRD image analysis method, an EDX spectrum image analysis method, an ultraviolet spectrum image analysis method, and an infrared spectrum image analysis method.
Further optimizing the technical scheme, when the SEM image analysis method is used for analyzing the glutamine modified titanium dioxide, the microscopic situation of the size, the geometric shape, the uniformity degree and the agglomeration degree of the nano titanium dioxide grains can be visually observed by using a picture shot by a transmission electron microscope.
Further optimizing the technical scheme, when the titanium dioxide modified by glutamine is analyzed by the XRD image analysis method, if the half peak width of the diffraction peak in the XRD pattern of the copper-doped titanium dioxide is widened and the peak position shifts, the copper ions are doped into the titanium dioxide crystal lattice; when the EDX spectral image analysis method is used for analyzing the glutamine modified titanium dioxide, the element content is determined by using an environmental electron scanning microscope with an X-ray energy spectrometer and adopting a selective area quantitative scanning analysis method.
Further optimizing the technical scheme, the ultraviolet spectral image analysis method and the infrared spectral image analysis method perform peak analysis on the ultraviolet visible light absorption spectrum and the infrared visible light absorption spectrum of the titanium dioxide when analyzing the glutamine modified titanium dioxide.
Compared with the prior art, the invention provides a synthesis method of titanium dioxide based on glutamine modification, which has the following beneficial effects:
according to the glutamine modification-based titanium dioxide synthesis method, copper ions are doped into nano-particle lattices, lattice stability and lattice energy are reduced, and the copper ions and glutamine react under a neutral condition to obtain glutamine-modified nano-titanium dioxide, so that the glutamine is used for modifying the nano-titanium dioxide, the glutamine-nano-titanium dioxide is synthesized, and ultraviolet, infrared, SEM, EDX and XRD characterization is carried out on the glutamine-modified nano-titanium dioxide for verification.
Drawings
FIG. 1 is a schematic flow chart of a method for synthesizing titanium dioxide based on glutamine modification according to the present invention;
FIG. 2 is a surface appearance picture of a nano titanium dioxide sample modified with copper ions observed by an SEM image analysis method in a titanium dioxide synthesis method based on glutamine modification according to the present invention;
FIG. 3 is a surface appearance picture of a glutamine-modified nano titanium dioxide sample observed by an SEM image analysis method in a glutamine-modified titanium dioxide synthesis method provided by the invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The first embodiment is as follows:
referring to fig. 1, a method for synthesizing titanium dioxide based on glutamine modification includes the following steps:
s1, selecting raw materials: providing a raw material for synthesizing glutamine modified titanium dioxide;
s2, preparing a mixed solution A: selecting butyl titanate, absolute ethyl alcohol and acetylacetone from raw materials, and mixing in a magnetic stirrer to obtain a mixed solution A;
s3, preparing a mixed solution B: selecting anhydrous ethanol and Cu (NO) from raw materials3)2Mixing the aqueous solution and concentrated HCl in a magnetic stirrer to obtain a mixed solution B;
s4, preparing sol: slowly dripping the mixed solution B into the mixed solution A to obtain sol with green color;
s5, preparing gel: putting the prepared sol into a magnetic stirrer, fully and uniformly mixing the sol and the magnetic stirrer, and standing and aging the sol to obtain wet gel;
s6, preparation of xerogel powder: drying the wet gel at 100 ℃ for 12h, grinding the dried gel into powder, roasting the powder at 300 ℃ for 1h to remove organic matters, roasting at 600 ℃ for 2h, and naturally cooling to room temperature to obtain dry gel powder;
s7, modified titanium dioxide: mixing and dissolving the xerogel powder and glutamine in deionized water, adjusting the pH value to 7 by using 0.1mol/L NaOH solution, and reacting for 6 hours to finish the modification of glutamine on titanium dioxide;
s8, analysis of titanium dioxide: and carrying out image analysis on the titanium dioxide modified by the glutamine.
Specifically, in S2, the mixing process of the mixed solution a includes the following specific contents: 10ml of butyl titanate was taken and put into a magnetic stirrer, and the butyl titanate was mixed with 8.6ml of absolute ethanol and 0.3ml of acetylacetone under magnetic stirring by the magnetic stirrer.
Specifically, in S3, the mixing process of the mixed solution B includes the following specific contents: under magnetic stirring with a magnetic stirrer, 8.6ml of absolute ethanol and 1.3ml of Cu (NO) with a mass concentration of 2%3)2The aqueous solution was mixed well with 0.1ml of concentrated HCl.
Specifically, in the step S5, the time for uniformly mixing the sol is 1 hour, and the temperature for standing and aging the sol is selected from room temperature conditions.
Specifically, in the S6, the prepared xerogel powder is modified by Cu2+Ionic titanium dioxide powder.
Specifically, in the S7, deionized water for dissolving xerogel powder and glutamine is heated, and the heating range is 40-50 ℃.
Specifically, in S8, the image analysis method includes SEM image analysis, XRD image analysis, EDX spectrum image analysis, ultraviolet spectrum image analysis, and infrared spectrum image analysis.
Specifically, when the SEM image analysis method is used for analyzing the glutamine modified titanium dioxide, the microscopic conditions of the size, the geometric shape, the uniformity degree and the agglomeration degree of the nano titanium dioxide crystal grains can be visually observed by using a picture shot by a transmission electron microscope.
Specifically, when the glutamine modified titanium dioxide is analyzed by the XRD image analysis method, if the half width of a diffraction peak in an XRD pattern of the copper-doped titanium dioxide is widened and the peak position is shifted, copper ions are doped into a titanium dioxide crystal lattice; when the EDX spectral image analysis method is used for analyzing the glutamine modified titanium dioxide, the element content is determined by using an environmental electron scanning microscope with an X-ray energy spectrometer and adopting a selective area quantitative scanning analysis method.
Specifically, the ultraviolet spectral image analysis method and the infrared spectral image analysis method perform peak analysis on the ultraviolet visible light absorption spectrum and the infrared visible light absorption spectrum of titanium dioxide when analyzing the glutamine modified titanium dioxide.
Example two:
the synthesized titanium dioxide was analyzed by SEM image analysis, XRD image analysis, EDX spectral image analysis, ultraviolet spectral image analysis, and infrared spectral image analysis using the method for synthesizing titanium dioxide based on glutamine modification described in example one.
SEM image analysis method: as shown in fig. 2, microscopic conditions such as the size, the geometric shape, the uniformity, the agglomeration degree and the like of the copper ion modified nano titanium dioxide crystal grains can be visually observed by using a photograph taken by a transmission electron microscope, and the sample crystal grains are irregular rectangles and have good dispersibility. As shown in fig. 3, the SEM result of the glutamine modified product showed that the morphology was changed from that of fig. 2, most of the particles were cubic, and the surface of the cube was loaded with fine spherical particles, which resulted in partial agglomeration.
XRD spectral image analysis method: the particle sizes of the titanium dioxide and the Cu/titanium dioxide are calculated according to a Sherrer formula and are respectively 29nm and 24-25 nm. As can be seen from the XRD pattern of the copper-doped titanium dioxide and the XRD pattern of the pure titanium dioxide, the half width of the diffraction peak in the XRD pattern of the copper-doped titanium dioxide becomes wider and the peak positions shift, indicating that copper ions have been incorporated into the titanium dioxide crystal lattice.
EDX spectral image analysis method: the element content determination is accomplished by using an environmental electron scanning microscope with an X-ray spectrometer and using a selected area quantitative scanning analysis method.
Ultraviolet spectrum image analysis method and infrared spectrum image analysis method: the copper-doped titanium dioxide sample has a wide absorption band of 400-800 nm. At 3425cm-1Near infrared absorption corresponds to H-N and O-H stretching vibrations, 1705cm-1The absorption peak at (a) is attributed to the stretching vibration of the C ═ O bond. The absorption vibration peak value of the copper-doped titanium dioxide is 500-520 cm-1The vibration peak in this interval is the Ti-O bond vibration peak. The sample of the purified composite particles is 3425cm and 1705cm-1And obvious characteristic absorption bands of glutamine exist at the positions, which fully indicates that partial glutamine molecules are modified on the surface of the Cu/titanium dioxide nano particle.
The invention has the beneficial effects that: according to the glutamine modification-based titanium dioxide synthesis method, copper ions are doped into nano-particle lattices, lattice stability and lattice energy are reduced, and the copper ions and glutamine react under a neutral condition to obtain glutamine-modified nano-titanium dioxide, so that the glutamine is used for modifying the nano-titanium dioxide, the glutamine-nano-titanium dioxide is synthesized, and ultraviolet, infrared, SEM, EDX and XRD characterization is carried out on the glutamine-modified nano-titanium dioxide for verification.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (10)

1. A synthesis method of titanium dioxide based on glutamine modification is characterized by comprising the following steps:
s1, selecting raw materials: providing a raw material for synthesizing glutamine modified titanium dioxide;
s2, preparing a mixed solution A: selecting butyl titanate, absolute ethyl alcohol and acetylacetone from raw materials, and mixing in a magnetic stirrer to obtain a mixed solution A;
s3, preparing a mixed solution B: selecting anhydrous ethanol, a Cu (NO3)2 aqueous solution and concentrated HCl from raw materials, and mixing in a magnetic stirrer to obtain a mixed solution B;
s4, preparing sol: slowly dripping the mixed solution B into the mixed solution A to obtain sol with green color;
s5, preparing gel: putting the prepared sol into a magnetic stirrer, fully and uniformly mixing the sol and the magnetic stirrer, and standing and aging the sol to obtain wet gel;
s6, preparation of xerogel powder: drying the wet gel at 100 ℃ for 12h, grinding the dried gel into powder, roasting the powder at 300 ℃ for 1h to remove organic matters, roasting at 600 ℃ for 2h, and naturally cooling to room temperature to obtain dry gel powder;
s7, modified titanium dioxide: mixing and dissolving the xerogel powder and glutamine in deionized water, adjusting the pH value to 7 by using 0.1mol/L NaOH solution, and reacting for 6 hours to finish the modification of glutamine on titanium dioxide;
s8, analysis of titanium dioxide: and carrying out image analysis on the titanium dioxide modified by the glutamine.
2. The method for synthesizing titanium dioxide based on glutamine modification according to claim 1, wherein in the step S2, the mixing process of the mixed solution A comprises the following specific contents: 10ml of butyl titanate was taken and put into a magnetic stirrer, and the butyl titanate was mixed with 8.6ml of absolute ethanol and 0.3ml of acetylacetone under magnetic stirring by the magnetic stirrer.
3. The method for synthesizing titanium dioxide based on glutamine modification according to claim 1, wherein in the step S3, the mixing process of the mixed solution B comprises the following specific steps: under magnetic stirring with a magnetic stirrer, 8.6ml of absolute ethyl alcohol and 1.3ml of Cu (NO3) with a mass concentration of 2%2The aqueous solution was mixed well with 0.1ml of concentrated HCl.
4. The method for synthesizing titanium dioxide based on glutamine modification according to claim 1, wherein in S5, the time for mixing the sol is 1h, and the temperature for standing and aging the sol is selected as the room temperature condition.
5. The method for synthesizing titanium dioxide based on glutamine modification according to claim 1, wherein in S6, the dry gel powder is Cu modified2+Ionic titanium dioxide powder.
6. The method for synthesizing titanium dioxide based on glutamine modification according to claim 1, wherein in the S7, deionized water for dissolving xerogel powder and glutamine is heated, and the heating range is 40-50 ℃.
7. The glutamine modification-based titanium dioxide synthesis method according to claim 1, wherein in the step S8, the image analysis method includes SEM image analysis, XRD image analysis, EDX spectrum image analysis, ultraviolet spectrum image analysis, and infrared spectrum image analysis.
8. The method for synthesizing titanium dioxide based on glutamine modification according to claim 7, wherein when analyzing the glutamine modified titanium dioxide, the SEM image analysis method is used for visually observing the microscopic conditions of the size, the geometric shape, the uniformity degree and the agglomeration degree of the nano titanium dioxide crystal grains by using a photo taken by a transmission electron microscope.
9. The glutamine modified titanium dioxide synthesis method according to claim 7, characterized in that, when the glutamine modified titanium dioxide is analyzed by the XRD image analysis method, if the half width of the diffraction peak in the XRD pattern of the copper-doped titanium dioxide is widened and the peak position is shifted, the copper ions are doped into the titanium dioxide crystal lattice; when the EDX spectral image analysis method is used for analyzing the glutamine modified titanium dioxide, the element content is determined by using an environmental electron scanning microscope with an X-ray energy spectrometer and adopting a selective area quantitative scanning analysis method.
10. The method for synthesizing titanium dioxide based on glutamine modification according to claim 7, wherein the ultraviolet spectral image analysis method and the infrared spectral image analysis method perform peak analysis on the ultraviolet visible light absorption spectrum and the infrared visible light absorption spectrum of titanium dioxide when analyzing the glutamine modified titanium dioxide.
CN202111067439.2A 2021-09-13 2021-09-13 Titanium dioxide synthesis method based on glutamine modification Pending CN113896236A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111067439.2A CN113896236A (en) 2021-09-13 2021-09-13 Titanium dioxide synthesis method based on glutamine modification
LU500966A LU500966B1 (en) 2021-09-13 2021-12-06 Method for synthesizing titanium dioxide based on glutamine modification

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111067439.2A CN113896236A (en) 2021-09-13 2021-09-13 Titanium dioxide synthesis method based on glutamine modification

Publications (1)

Publication Number Publication Date
CN113896236A true CN113896236A (en) 2022-01-07

Family

ID=79027769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111067439.2A Pending CN113896236A (en) 2021-09-13 2021-09-13 Titanium dioxide synthesis method based on glutamine modification

Country Status (2)

Country Link
CN (1) CN113896236A (en)
LU (1) LU500966B1 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151023A (en) * 2005-01-27 2008-03-26 弗拉梅技术公司 Copolyhydroxyalkylglutamines which are functionalised with hydrophobic groups and applications thereof, such as in therapeutics
US20100119608A1 (en) * 2008-11-11 2010-05-13 Jinhyuk Fred Chung Synthesis of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles
CN101890343A (en) * 2010-06-29 2010-11-24 浙江大学 Low temperature surface modification method for titanium dioxide nanocrystal
CN103021666A (en) * 2012-12-03 2013-04-03 彩虹集团公司 Method for preparing compound titanium dioxide film
CN105194679A (en) * 2015-09-01 2015-12-30 郑州大学 Preparation method and application of titanium dioxide-graphene oxide composite material modified by hyaluronic acid of antitumor drug nanometer layer
CN107022517A (en) * 2017-05-25 2017-08-08 句容亿格纳米材料厂 A kind of method for improving glutamine stability in stem cell media
CN109244243A (en) * 2018-09-06 2019-01-18 中国石油大学(华东) A kind of L-cysteine modification TiO2The methods and applications of electron transfer layer
CN109876805A (en) * 2017-12-06 2019-06-14 天津发洋环保科技有限公司 A kind of Ag doping TiO2The preparation method of nano photo-catalytic
CN109999888A (en) * 2019-05-06 2019-07-12 西北师范大学 The preparation of copper and nitrogen co-doped modified titanium dioxide photocatalyst and the application for toluene of degrading
CN110124057A (en) * 2019-06-06 2019-08-16 天津医科大学总医院 A kind of anti-tumor drug or pharmaceutical carrier of the cyclodextrin comprising glutamine modification
CN111762815A (en) * 2020-07-07 2020-10-13 上海应用技术大学 Preparation method of copper-doped titanium dioxide nano powder based on controllable hydrolysis method
CN111903709A (en) * 2020-08-11 2020-11-10 北京锦绣新技术发展有限公司 Preparation method of sterilizing disinfectant for killing coronavirus

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151023A (en) * 2005-01-27 2008-03-26 弗拉梅技术公司 Copolyhydroxyalkylglutamines which are functionalised with hydrophobic groups and applications thereof, such as in therapeutics
US20100119608A1 (en) * 2008-11-11 2010-05-13 Jinhyuk Fred Chung Synthesis of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles
CN101890343A (en) * 2010-06-29 2010-11-24 浙江大学 Low temperature surface modification method for titanium dioxide nanocrystal
CN103021666A (en) * 2012-12-03 2013-04-03 彩虹集团公司 Method for preparing compound titanium dioxide film
CN105194679A (en) * 2015-09-01 2015-12-30 郑州大学 Preparation method and application of titanium dioxide-graphene oxide composite material modified by hyaluronic acid of antitumor drug nanometer layer
CN107022517A (en) * 2017-05-25 2017-08-08 句容亿格纳米材料厂 A kind of method for improving glutamine stability in stem cell media
CN109876805A (en) * 2017-12-06 2019-06-14 天津发洋环保科技有限公司 A kind of Ag doping TiO2The preparation method of nano photo-catalytic
CN109244243A (en) * 2018-09-06 2019-01-18 中国石油大学(华东) A kind of L-cysteine modification TiO2The methods and applications of electron transfer layer
CN109999888A (en) * 2019-05-06 2019-07-12 西北师范大学 The preparation of copper and nitrogen co-doped modified titanium dioxide photocatalyst and the application for toluene of degrading
CN110124057A (en) * 2019-06-06 2019-08-16 天津医科大学总医院 A kind of anti-tumor drug or pharmaceutical carrier of the cyclodextrin comprising glutamine modification
CN111762815A (en) * 2020-07-07 2020-10-13 上海应用技术大学 Preparation method of copper-doped titanium dioxide nano powder based on controllable hydrolysis method
CN111903709A (en) * 2020-08-11 2020-11-10 北京锦绣新技术发展有限公司 Preparation method of sterilizing disinfectant for killing coronavirus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANGQIANG HUANG ET AL.: "Preparation and Characterization of Visible-Light-Activated Fe-N Co-Doped TiO2 and Its Photocatalytic Inactivation Effect on Leukemia Tumors", 《INTERNATIONAL JOURNAL OF PHOTOENERGY》 *

Also Published As

Publication number Publication date
LU500966B1 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
Wang et al. Correlation between Li+ adsorption capacity and the preparation conditions of spinel lithium manganese precursor
CN108706637B (en) A kind of preparation method of adjustable magnetic iron oxide mesomorphic material of uniform size
Fu et al. Synthesis and luminescent properties of SnO2: Eu nanopowder via polyacrylamide gel method
CN108821311B (en) Preparation method of prussian white mesomorphic material with fine and adjustable ferromanganese component
CN110330048B (en) Preparation method of nano yttrium oxide powder
Jia et al. pH value-dependant growth of α-Fe2O3 hierarchical nanostructures
Nilavazhagan et al. Structural, optical and morphological properties of La, Cu co-doped SnO2 nanocrystals by co-precipitation method
CN106753357B (en) Preparation method of PbS quantum dots
KR20080080350A (en) Methods for production of metal oxide nano particles with controlled properties, and nano particles and preparations produced thereby
Mohamad et al. Synthesis of alumina nanoparticles by sol-gel method and their applications in the removal of copper ions (Cu2+) from the solution
Gao et al. Understanding the growth mechanism of wurtzite Cu2ZnSnS4 nanocrystals and the photodegradation properties
CN108264342A (en) A kind of high-purity magnesium-aluminum spinel powder and preparation method thereof
Nikmehr et al. Zn-based MOFs materials fabricated by mechanochemical ball milling and hydrothermal method and derived metal oxides
CN108083315B (en) Preparation method of spherical thorium dioxide nano material with sheet surface structure and spherical thorium dioxide particles obtained by preparation method
CN113896236A (en) Titanium dioxide synthesis method based on glutamine modification
Koao et al. Effect of pH on the properties of ZnO nanostructures prepared by chemical bath deposition method
Vaja et al. Synthesis of CeO2 nanoparticles on the mesoporous silica support via nanocasting
CN107445174B (en) Lithium battery cathode material Li2FeSiO4And method for preparing the same
Li et al. Effect of process parameters on the synthesis of YAG nano-crystallites in supercritical solvent
Yang et al. Novel 3D octahedral La2Sn2O7: Eu3+ microcrystals: Hydrothermal synthesis and photoluminescence properties
CN112266649B (en) Cyan material and preparation method thereof, near-infrared high-reflection blue coating and preparation method thereof
Ueno et al. Controlled synthesis of star-shaped zinc oxide particles at low temperatures and their quantum size effect
Yadav et al. Optical and photoluminescence response driven by sintering temperature in LaFeO3 nano-perovskites
Wu et al. Synthesis of BaMgAl10O17: Eu2+ particles with small grain size and regular morphology
Mamonova et al. Synthesis and study of Y 2 O 3: Eu 3+ nanoparticles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination